Gold prices steady ahead of Fed decision, Trump’s tariff deadline
In a recent transaction, Grigorios Siokas, the Chief Executive Officer of Cosmos Health Inc. (NASDAQ:COSM), a $12.2 million market cap healthcare company currently trading at $0.45, acquired a substantial amount of the company’s stock. According to InvestingPro analysis, the company maintains a Fair Value rating suggesting potential upside from current levels. According to a filing with the Securities and Exchange Commission, Siokas obtained 147,563 shares of common stock at a price of $0.447 per share. The acquisition, valued at approximately $65,960, was part of a debt exchange agreement between Siokas and the company. This transaction increases Siokas’ direct ownership to a total of 5,808,883 shares. The exchange was executed on May 20, 2025, reflecting the fair market value of the stock on that date. While the company faces challenges with its debt burden and cash burn rate, analysts predict profitability in 2025. Unlock deeper insights into insider trading patterns and 8 additional key metrics with InvestingPro.
In other recent news, Cosmos Health Inc. has been granted an additional 180-day period by the Nasdaq Stock Market to meet the minimum bid price requirement, extending the deadline to November 3, 2025. The company aims to regain compliance by raising its stock price to at least $1.00 per share for ten consecutive business days. In a separate development, Cosmos Health’s CEO, Greg Siokas, has increased his stake in the company by purchasing 1,466,764 common shares, amounting to $526,000. This move reflects Siokas’s confidence in the company’s value creation and strategic direction.
Additionally, Cosmos Health has secured a significant contract manufacturing agreement through its subsidiary, Cana Laboratories, with Pharmex S.A. This deal involves producing 300,000 bottles per year of the antiseptic drug AMBITASOL 1L over five years. Expanding its market presence, Cosmos Health has also entered the Albanian market with its Sky Premium Life food supplements brand, partnering with Pharma Cell for distribution. The initial order from Pharma Cell is valued at $300,000, with potential for future growth. These developments highlight Cosmos Health’s ongoing efforts to expand its global footprint and enhance its revenue streams.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.